An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cue Biopharma, Inc. (Nasdaq: CUE) will present at the 2024 American Society of Clinical Oncology Annual Meeting. The company will showcase Phase 1 trials of CUE-101 and CUE-102 in head and neck cancer and recurrent/metastatic cancers. There will be an oral abstract and poster presentation, with a Business Update call and webcast scheduled for June 2024.
Cue Biopharma, Inc. (Nasdaq: CUE) parteciperà al Congresso Annuale 2024 della Società Americana di Oncologia Clinica. La compagnia presenterà i risultati delle prove di Fase 1 di CUE-101 e CUE-102 per i tumori della testa e del collo e i tumori ricorrenti/metastatici. Saranno predisposti una presentazione orale di un abstract e un poster, con una telefonata di aggiornamento aziendale e un webcast programmato per giugno 2024.
Cue Biopharma, Inc. (Nasdaq: CUE) presentará en la Reunión Anual de la Sociedad Americana de Oncología Clínica de 2024. La empresa expondrá los ensayos de Fase 1 de CUE-101 y CUE-102 en cánceres de cabeza y cuello y cánceres recurrentes/metastásicos. Habrá una presentación oral de un resumen y una presentación de pósters, junto con una llamada de Actualización Empresarial y una webcast programada para junio de 2024.
Cue Biopharma, Inc.(나스닥: CUE)는 2024년 미국 임상 종양학회 연례 회의에서 발표할 예정입니다. 이 회사는 두경부암 및 재발성/전이성 암에 대한 CUE-101 및 CUE-102의 1상 시험을 소개할 것입니다. 구두 초록 발표와 포스터 세션이 있으며, 2024년 6월에 비즈니스 업데이트 통화 및 웹캐스트가 예정되어 있습니다.
Cue Biopharma, Inc. (Nasdaq: CUE) présentera lors de la Réunion Annuelle 2024 de la Société Américaine d’Oncologie Clinique. La société exposera les essais de Phase 1 de CUE-101 et CUE-102 pour les cancers de la tête et du cou et les cancers récurrents/métastatiques. Une présentation orale d’un résumé et une présentation d’affiches sont prévues, avec une mise à jour commerciale par appel et webcast programmés pour juin 2024.
Cue Biopharma, Inc. (Nasdaq: CUE) wird auf der Jahrestagung 2024 der Amerikanischen Gesellschaft für Klinische Onkologie präsentieren. Das Unternehmen wird Phase-1-Studien von CUE-101 und CUE-102 bei Kopf- und Halskrebs sowie rezidivierenden/metastasierenden Krebserkrankungen vorstellen. Es ist eine mündliche Präsentation eines Abstracts sowie eine Posterpräsentation geplant, mit einem Business-Update-Anruf und einem Webcast für Juni 2024.
Positive
None.
Negative
None.
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.
The presentations will highlight the Company’s Phase 1 trials of its lead interleukin 2 (IL-2)-based biologics, CUE-101 in recurrent/metastatic head and neck cancer and CUE-102 in Wilms’ Tumor 1 positive recurrent/metastatic cancers.
The Company will host a Business Update call and webcast in June 2024 that will include a discussion on the clinical progress and associated data presented at ASCO on June 1 and June 4. Call details will be issued prior to the event.
Oral Abstract and Poster Details
Abstract Number: 6004 Title: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC). Presenter: Douglas R. Atkins, M.D., Professor of Medicine, Washington University School of Medicine Session Type and Title: Oral Abstract Session; Head and Neck Cancer Session Date and Time: June 4, 2024, 9:45 AM-12:45 PM CDT
Abstract Number: 3553 Title: A phase 1 open-label, dose escalation and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201 positive disease and WT1-positive recurrent/metastatic cancers. Presenter: Nataliya Uboha, M.D., Ph.D. University of Wisconsin Carbone Cancer Center Session Type and Title: Poster Session; Gastrointestinal Cancer, Colorectal and Anal Session Date and Time: June 1, 2024, 1:30 PM-4:30 PM CDT
The oral abstract and poster presentations will be available in the Investor & Media section of the Company’s website at www.cuebiopharma.com under Scientific Publications and Presentations, following ASCO.
About Cue Biopharma Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
What is Cue Biopharma presenting at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting?
Cue Biopharma will present an oral abstract and poster at the ASCO Annual Meeting, featuring Phase 1 trials of its lead interleukin 2 (IL-2)-based biologics, CUE-101 and CUE-102.
What are the specific Phase 1 trials that Cue Biopharma will highlight at ASCO?
Cue Biopharma will highlight Phase 1 trials of CUE-101 in recurrent/metastatic head and neck cancer and CUE-102 in Wilms' Tumor 1 positive recurrent/metastatic cancers.
Who will present the oral abstract for Cue Biopharma at ASCO?
The oral abstract for Cue Biopharma at ASCO will be presented by Douglas R. Atkins, M.D., Professor of Medicine at Washington University School of Medicine.
When will Cue Biopharma host a Business Update call and webcast?
Cue Biopharma will host a Business Update call and webcast in June 2024 to discuss the clinical progress and data presented at ASCO on June 1 and June 4.
Where can the oral abstract and poster presentations be accessed following ASCO?
The oral abstract and poster presentations will be available in the Investor & Media section of Cue Biopharma's website at www.cuebiopharma.com under Scientific Publications and Presentations.
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
